Lupin FY2026 Financial Results Deep Dive | ₹2,74,875 Cr Sales

Filing Analysis

Key Event

Lupin Limited (LUPIN) announced audited FY2026 financial results on May 7, 2026, reporting robust growth:

• FY2026 sales: ₹2,74,875 Cr, up 23.9% YoY
• PAT: ₹53,555 Cr, up 62.0% YoY
• Q4 FY2026 revenue: ₹73,919 Cr, up 32.9% YoY (U.S. +56.9%, India +11.5%)
• EBITDA margin: Expanded to 35.5% from 24.7%
• Board recommended ₹18/share dividend (900% on ₹2 face value), subject to AGM approval
• Net debt: -₹46,358 Cr (net cash position)

Other highlights: ₹5,816.9M antitrust provision; ₹20,902.7M VISUfarma acquisition; cash reserves at ₹41,677.3M.

Investor Implications

• Growth drivers: Strong U.S./India performance, complex generics, biosimilars (e.g., Semaglutide), respiratory launches signal sustained momentum.
• Margin expansion (Q4 EBITDA 29.4%) reflects operational efficiency.
• Dividend boost rewards shareholders; net cash strengthens balance sheet for M&A.
• Risks: Litigation provisions, auditor change to Deloitte post-AGM.
• Stock reaction: +0.7% to ₹2,460.1 on May 7, 2026.

Financial Snapshot

Lupin P/E (39.1) trades at a premium to pharma industry average (~21%).

Takeaway

Exceptional FY2026 growth, margin gains, and rich dividend signal strong shareholder value creation amid U.S./India tailwinds—positive for long-term holders.